FDA — authorised 23 November 1983
- Application: NDA018831
- Marketing authorisation holder: HOSPIRA
- Local brand name: TRACRIUM
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Atracurium in United States
FDA authorised Atracurium on 23 November 1983
Marketing authorisations
FDA — authorised 23 December 1996
- Application: ANDA074632
- Marketing authorisation holder: HOSPIRA
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 18 July 1997
- Application: ANDA074901
- Marketing authorisation holder: HIKMA
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 September 1997
- Application: ANDA074824
- Marketing authorisation holder: BAXTER HLTHCARE
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 28 July 1998
- Application: ANDA074945
- Marketing authorisation holder: WATSON PHARMS TEVA
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 February 2012
- Application: ANDA091489
- Marketing authorisation holder: MEITHEAL
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 18 October 2012
- Application: ANDA090761
- Marketing authorisation holder: HOSPIRA INC
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 8 April 2015
- Application: ANDA206011
- Marketing authorisation holder: EUGIA PHARMA
- Local brand name: ATRACURIUM BESYLATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
Pricing & reimbursement
- annual_list: USD 0.00 per year
Atracurium in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Atracurium approved in United States?
Yes. FDA authorised it on 23 November 1983; FDA authorised it on 23 December 1996; FDA authorised it on 18 July 1997.
Who is the marketing authorisation holder for Atracurium in United States?
HOSPIRA holds the US marketing authorisation.
What does Atracurium cost in United States?
annual_list: USD 0.00 per year. Final patient cost depends on reimbursement and any patient access scheme.